Mara Persano
AuthID: R-00K-PAZ
11
TITLE: Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Presa, J.; Masi, G.; Yoo, C.; Lonardi, S.; Piscaglia, F.; Iavarone, M. A.; Tamburini, E.; Cabibbo, G.; Silletta, M.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Presa, J.; Masi, G.; Yoo, C.; Lonardi, S.; Piscaglia, F.; Iavarone, M. A.; Tamburini, E.; Cabibbo, G.; Silletta, M.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
INDEXED IN: 
WOS
WOS12
TITLE: Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Bergamo, F.; Iavarone, M. A.; Cabibbo, G.; Foschi, F. G.; Piscaglia, F.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Bergamo, F.; Iavarone, M. A.; Cabibbo, G.; Foschi, F. G.; Piscaglia, F.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
INDEXED IN: WOS
WOS13
TITLE: Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
AUTHORS: Rimini, M.; Amadeo, E.; Vitiello, F.; Foti, S.; Persano, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Piscaglia, F.; Masi, G.; Yoo, C.; Lonardi, S.; Rossari, F.; Camera, S.; Gardini, A. Casadei; Presa, J.;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
AUTHORS: Rimini, M.; Amadeo, E.; Vitiello, F.; Foti, S.; Persano, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Piscaglia, F.; Masi, G.; Yoo, C.; Lonardi, S.; Rossari, F.; Camera, S.; Gardini, A. Casadei; Presa, J.;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
INDEXED IN: WOS
WOS14
TITLE: Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Bergamo, F.; Iavarone, M. A.; Cabibbo, G.; Foschi, F. G.; Piscaglia, F.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
AUTHORS: Persano, M.; Rimini, M.; Tada, T.; Suda, G.; Shimose, S.; Kudo, M.; Yoo, C.; Cheon, J.; Finkelmeier, F.; Lim, H. Y.; Presa, J.; Masi, G.; Bergamo, F.; Iavarone, M. A.; Cabibbo, G.; Foschi, F. G.; Piscaglia, F.; Cascinu, S.; Scartozzi, M.; Gardini, A. Casadei;
PUBLISHED: 2023, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 34
INDEXED IN: WOS
WOS